The best treatment for rheumatoid arthritis (RA) is early, aggressive use of disease-modifying drugs, with methotrexate as the cornerstone of first-line therapy. Starting treatment within months of diagnosis gives you the highest chance of reaching remission, which roughly 25% to 35% of patients achieve depending on how remission is measured. The goal isn’t just managing pain. It’s stopping the immune system from destroying your joints in the first place.
Why Methotrexate Comes First
Methotrexate is the starting point for nearly every RA treatment plan. International guidelines from both American and European rheumatology organizations agree: methotrexate should be part of the first treatment strategy. It works by dialing down the overactive immune response that causes joint inflammation and damage, and it’s been the backbone of RA treatment for decades because it’s effective, well-studied, and relatively affordable.
The usual starting dose is 7.5 mg taken once a week, not daily. This is an important distinction because methotrexate can cause serious harm if taken more frequently than prescribed. Your doctor will typically prescribe folic acid alongside it to reduce side effects like nausea and mouth sores. When you first start, expect blood tests every one to two weeks to monitor your liver and kidneys. Once your dose is stable and working, that drops to every two to three months.
Methotrexate doesn’t work overnight. It can take several weeks to months before you feel a meaningful difference, which is why short-term steroids are often added at the beginning to bridge the gap. These corticosteroids rapidly suppress inflammation and relieve symptoms while you wait for methotrexate to kick in. Guidelines recommend tapering off steroids within three months. Research shows that longer steroid courses and higher starting doses make it significantly harder to stop them later, creating a cycle of dependence that adds up to serious cumulative side effects like bone thinning and weight gain.
If you can’t take methotrexate due to liver problems, kidney disease, or intolerable side effects, two alternatives are typically considered as replacements: leflunomide and sulfasalazine. Both are in the same broad class of conventional disease-modifying drugs.
What Happens If Methotrexate Isn’t Enough
Not everyone responds adequately to methotrexate alone. When that happens, the next step depends on how severe your disease is and whether you have features that predict worse outcomes, such as high levels of inflammation markers, early joint erosion on imaging, or persistently swollen joints despite treatment.
If you don’t have these poor prognostic signs, your rheumatologist will likely try combining methotrexate with another conventional disease-modifying drug before moving to more advanced options. But if you do have signs of aggressive disease, the guidelines shift toward adding a biologic or a targeted oral medication sooner rather than later. The treatment target is always remission or, if that’s not realistic, the lowest possible disease activity.
Biologic Therapies
Biologics are a class of drugs made from living cells that target specific parts of the immune system rather than suppressing it broadly. They’re typically given as injections or infusions and are added to methotrexate rather than replacing it, since the combination tends to work better than either alone.
The most commonly prescribed biologics for RA are TNF inhibitors, which block a protein called tumor necrosis factor that drives inflammation. There are five TNF inhibitors available, and they’ve been used in RA for over two decades with extensive safety data. If a TNF inhibitor doesn’t work or stops working, you have several options: try a different TNF inhibitor, or switch to a biologic with a completely different mechanism. These include drugs that block a different inflammatory protein called interleukin-6, drugs that reduce the activity of specific white blood cells called T-cells, and drugs that deplete another type of immune cell called B-cells. Your rheumatologist will choose based on your specific disease pattern and other health conditions.
Biosimilars, which are near-identical copies of original biologic drugs, have made these treatments more accessible. While individual treatment costs drop modestly with biosimilars, the bigger effect has been allowing more patients to access biologic therapy overall. A study from one rheumatology center found that the average cost per biologic user decreased after biosimilar introduction, but total spending stayed roughly the same because more patients were started on treatment.
JAK Inhibitors: Effective but With Caveats
JAK inhibitors are oral medications (pills, not injections) that block specific enzymes involved in the inflammatory process. Three are currently approved for RA. They’re effective, and the convenience of a pill rather than an injection appeals to many patients. However, they carry important safety considerations that have reshaped how doctors prescribe them.
A large safety trial comparing one JAK inhibitor to TNF-blocking biologics found higher rates of serious cardiovascular events like heart attack and stroke, certain cancers (particularly lymphoma and lung cancer), and blood clots with the JAK inhibitor. The FDA now requires its strongest warning label on all three approved JAK inhibitors for RA. Because of these findings, current guidelines recommend that JAK inhibitors be considered primarily for patients who’ve already tried a biologic without success, and that doctors weigh specific risk factors before prescribing them. If you’re over 65, a current or past smoker, or have cardiovascular risk factors, your doctor will be especially cautious.
Exercise and Physical Therapy
Medication is the foundation, but physical activity plays a genuine role in managing RA. The right exercise program improves joint mobility, maintains muscle strength, and reduces fatigue without worsening inflammation. The key is matching the type of exercise to what your joints can handle at any given time.
For joints that aren’t actively inflamed, daily stretching of all major joints helps prevent the stiffness and loss of range that can quietly accumulate over months and years. Strengthening exercises are also important for non-inflamed joints. Research from Johns Hopkins shows that even brief daily isometric contractions, where you tense a muscle without moving the joint, held for about 10 seconds at low effort, can maintain strength and prevent injury.
Aerobic conditioning matters too. Studies have demonstrated that programs combining strengthening exercises with cycling can improve muscle strength without triggering disease flares. Pool-based exercise is particularly well-suited for RA because the water reduces stress on joints while the warmth helps ease pain and muscle tension. Researchers have documented improvements in both strength and endurance from water exercise programs. Whatever form of exercise you choose, the principle is to start slowly and increase gradually, paying attention to any new joint swelling or pain that persists after activity.
Diet and Inflammation
Anti-inflammatory diets, particularly Mediterranean-style eating patterns rich in fish, olive oil, vegetables, and whole grains, are frequently recommended for RA. The logic is sound: these foods contain compounds that can influence inflammatory pathways. However, the clinical evidence for dietary changes directly reducing RA disease activity is modest. A randomized controlled trial that put 50 RA patients on a specifically designed anti-inflammatory diet for 10 weeks found no significant differences in key disease activity measures, including joint tenderness, joint swelling, and inflammatory blood markers, compared to a typical diet.
This doesn’t mean diet is irrelevant. Maintaining a healthy weight reduces mechanical stress on joints and lowers systemic inflammation. Eating well supports overall health, which matters when you’re managing a chronic disease and taking medications that affect your immune system. But diet alone won’t substitute for disease-modifying drugs, and dramatic dietary claims about “curing” RA aren’t supported by the data.
Realistic Expectations for Remission
Remission in RA means minimal or no joint inflammation, not necessarily a permanent cure. How often it’s achieved depends heavily on how it’s defined. A large study of over 2,000 RA patients found remission rates ranging from about 25% using strict criteria to over 60% using more lenient measures. Studies from Euro-American populations using moderate criteria found remission in roughly 14% to 20% of patients. These numbers reflect real-world practice, where treatment adherence, delays in diagnosis, and individual biology all play a role.
Even when full remission isn’t reached, the broader goal of low disease activity, meaning well-controlled symptoms with minimal joint damage progression, is achievable for a much larger proportion of patients. The most important factor in your outcome is starting effective treatment early and adjusting it promptly when it’s not working. Guidelines recommend reassessing every three to six months and changing strategy if the treatment target hasn’t been met.